Topical cyclosporin A in the management of vernal keratoconjunctivitis

Purpose To study the efficacy of topical cyclosporin A in children with ver nal keratoconjunctivitis in a prospective randomised double-masked trial. M ethods Twenty-four children between 5 and 16 years of age were randomly tre ated with cyclosporin A (CsA) and placebo (vehicle) and followed up for 4 m onths. Methods Twenty-four children between 5 and 16 years of age were randomly tr eated with cyclosporin A (CsA) and placebo (vehicle) and followed up for 4 months. Results Of the 12 patients given CsA, 11 showed symptomatic improvement by 7 days of starting treatment whereas only 3 patients in the placebo group s howed mild symptomatic improvement. Conclusions Topical cyclosporin is a safe and effective treatment in vernal kerato conjunctivitis.